LT3672571T - Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą - Google Patents

Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą

Info

Publication number
LT3672571T
LT3672571T LTEPPCT/IB2018/056281T LTIB2018056281T LT3672571T LT 3672571 T LT3672571 T LT 3672571T LT IB2018056281 T LTIB2018056281 T LT IB2018056281T LT 3672571 T LT3672571 T LT 3672571T
Authority
LT
Lithuania
Prior art keywords
phenyl
dimorpholin
triazin
piperidin
dimethylamino
Prior art date
Application number
LTEPPCT/IB2018/056281T
Other languages
English (en)
Inventor
James Joseph HUSSEY
Andrew Gilbert BRIGHT
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of LT3672571T publication Critical patent/LT3672571T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/IB2018/056281T 2017-08-25 2018-08-20 Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą LT3672571T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762550007P 2017-08-25 2017-08-25
US201862681720P 2018-06-07 2018-06-07
US201862703022P 2018-07-25 2018-07-25
PCT/IB2018/056281 WO2019038657A1 (en) 2017-08-25 2018-08-20 AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING 1- (4 - {[4- (DIMETHYLAMINO) PIPERIDIN-1-YL] CARBONYL} PHENYL) -3- [4- (4,6-DIMORPHOLIN-4-YL-1,3,5) triazin-2-yl) phenyl] urea

Publications (1)

Publication Number Publication Date
LT3672571T true LT3672571T (lt) 2021-12-10

Family

ID=63586769

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IB2018/056281T LT3672571T (lt) 2017-08-25 2018-08-20 Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą

Country Status (14)

Country Link
US (2) US11541058B2 (lt)
EP (1) EP3672571B1 (lt)
JP (1) JP7313126B2 (lt)
CY (1) CY1124820T1 (lt)
ES (1) ES2895370T3 (lt)
HR (1) HRP20211985T1 (lt)
HU (1) HUE056743T2 (lt)
LT (1) LT3672571T (lt)
PL (1) PL3672571T3 (lt)
PT (1) PT3672571T (lt)
RS (1) RS62663B1 (lt)
SI (1) SI3672571T1 (lt)
TW (1) TW201919635A (lt)
WO (1) WO2019038657A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2956225T3 (es) * 2018-06-07 2023-12-15 Pfizer Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
AU2022320615A1 (en) 2021-07-26 2024-03-14 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
CA2472342A1 (en) 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
JP2011520979A (ja) 2008-05-23 2011-07-21 ワイス・エルエルシー PI3キナーゼおよびmTOR阻害剤としてのトリアジン化合物
US10022381B2 (en) 2008-05-23 2018-07-17 Pfizer Inc. Triazine compounds as PI3 kinase and mTOR inhibitors
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US20140220112A1 (en) 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
DK3233054T3 (da) 2014-12-17 2021-08-02 Pfizer Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration
ES2956225T3 (es) 2018-06-07 2023-12-15 Pfizer Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea

Also Published As

Publication number Publication date
CY1124820T1 (el) 2022-11-25
TW201919635A (zh) 2019-06-01
RS62663B1 (sr) 2021-12-31
EP3672571B1 (en) 2021-10-06
HUE056743T2 (hu) 2022-03-28
WO2019038657A1 (en) 2019-02-28
HRP20211985T1 (hr) 2022-04-01
SI3672571T1 (sl) 2022-01-31
US20230218628A1 (en) 2023-07-13
PL3672571T3 (pl) 2022-01-31
PT3672571T (pt) 2021-11-02
ES2895370T3 (es) 2022-02-21
US20210267988A1 (en) 2021-09-02
EP3672571A1 (en) 2020-07-01
US11541058B2 (en) 2023-01-03
JP7313126B2 (ja) 2023-07-24
JP2019038799A (ja) 2019-03-14

Similar Documents

Publication Publication Date Title
PH12016501794A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IL252368B (en) 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it
GB2572305B (en) Heterocyclic urea compound, and drug composition and application thereof
IL237378B (en) Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them
IL246545B (en) History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them
EP3626709A4 (en) INDAZOLE COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF
IL247077B (en) A pharmaceutical preparation containing a diamino heterocyclic carboxamide compound as an active ingredient
IL279270A (en) Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
IL273573A (en) Nitrogen-containing heteroaryl compound and medicinal use thereof
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
CY1124527T1 (el) Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση
LT3672571T (lt) Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
IL243650A0 (en) History of 1-(piperazine-1-yl)-2-([4,2,1]triazol-1-yl)-ethanone
PH12017502017A1 (en) Pharmaceutical compositions
WO2014105777A8 (en) Cobicostat dichlohydrate salt
IT201700098438A1 (it) Testiera per cavalli
IL257671A (en) Salts of 1-(4-(2-((1-(4,3-difluorophenyl)-1h-pyrazol-3-yl(methoxy)ethyl)piperazin-1-yl)ethanone
UA37000S (uk) Диван кутовий «bruno»
TH1601002081A (th) รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต
UA33872S (uk) Кутовий диван «renata»
TH168885A (th) อนุพันธ์ 1-(พิเพอราซิน-1-อิล)-2-([1,2,4]ไตรอะโซล-1-อิล)-เอทาโนน